Premium
Pathogen reduced plasma products: a clinical practice scientific review from the AABB
Author(s) -
Cushing Melissa M.,
Pagano Monica B.,
Jacobson Jessica,
Schwartz Joseph,
Grossman Brenda J.,
Kleinman Steven,
Han Mi Ah,
Cohn Claudia S.
Publication year - 2019
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/trf.15435
Subject(s) - pathogen , medicine , immunology
BACKGROUND A small body of literature assessing the efficacy and safety of pathogen reduced (PR) plasma has been published. STUDY DESIGN AND METHODS An AABB committee systematically reviewed the literature and graded the clinical trial evidence with the assistance of a GRADE expert. RESULTS Most studies identified were low quality and had a small sample size; in addition, efficacy and safety were monitored in many different ways making it difficult to quantify therapeutic benefit and risk. The data analyzed in this systematic review showed that pathogen inactivation did not adversely affect the efficacy of S/D or amotosalen plasma transfusions in any patient population studied. In addition, there were no significant safety issues for these patient populations, other than the specific contraindications noted in their respective package inserts. CONCLUSION Larger, well‐designed trials are needed to further evaluate the efficacy and safety of all of the PR plasma products.